Compounds > benzosuberone
Page last updated: 2024-11-06

benzosuberone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benzosuberone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID70003
SCHEMBL ID163580
MeSH IDM000601246

Synonyms (54)

Synonym
6,8,9-tetrahydrobenzobicyclohepten-5-one
1-benzosuberanone
benzsuberone
2,3-benzosuberone
.alpha.-benzosuberone
nsc-87961
benzo[b]cycloheptan-1-one
6,8,9-tetrahydrobenzocyclohepten-5-one
nsc87961
1-benzosuberone
5-benzocycloheptanone
5h-benzocyclohepten-5-one,7,8,9-tetrahydro-
HMS1788C07
6,7,8,9-tetrahydrobenzocyclohepten-5-one
EN300-17368
inchi=1/c11h12o/c12-11-8-4-2-6-9-5-1-3-7-10(9)11/h1,3,5,7h,2,4,6,8h
5h-benzocyclohepten-5-one, 6,7,8,9-tetrahydro-
826-73-3
6,7,8,9-tetrahydro-5h-benzo[7]annulen-5-one
2-cyclohepten,1-one,2,3-benzo
1-benzosuberone, 99%
6,7,8,9-tetrahydrobenzo[7]annulen-5-one
6,7,8,9-tetrahydro-5h-benzocyclohepten-5-one
T1347
AKOS001053244
6,7,8,9-tetrahydrobenzobicyclohepten-5-one
alpha-benzosuberone
unii-pk6cal2phu
benzo(b)cycloheptan-1-one
einecs 212-558-4
nsc 87961
pk6cal2phu ,
STL281968
6,7,8,9-tetrahydro-5-benzocycloheptenone
FT-0620844
BBL027450
SCHEMBL163580
DTXSID50231908
benzosuberone
6,7,8,9-tetrahydro-5h-benzocyclohepten- 5-one
6,7,8,9-tetrahydro-benzocyclohepten-5-one
bezosuberone
6,7,8,9-tetrahydro-5h-benzo[a]cyclohepten-5-one
6,7,8,9-tetrahydro-5h-benzo[a]cyclohepten-5-one #
W-104166
benzocycloheptanone
F0001-2118
mfcd00004144
Z56922160
SY051585
F14617
AS-15409
AMY15552
CS-0070941

Research Excerpts

Treatment

ExcerptReferenceRelevance
"The benzosuberones 1a,b were treated with 3-mercaptopropanoic acid to give compounds 21a,b, which were cyclized to tricyclic thiopyran-4(5H)-one derivatives 22a,b."( Synthesis and Antimicrobial Evaluation of a New Series of Heterocyclic Systems Bearing a Benzosuberone Scaffold.
Ali, KA; Alsayed, AS; Awad, HM; El-Galil E Amr, A; El-Salam, OI; Elwahab, AA, 2015)		1.12
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (86.67)24.3611
2020's2 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.76 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.91 (4.65)
Search Engine Demand Index24.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (13.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
coumarin
2H-chromen-2-one: coumarin derivative		7.110coumarinsfluorescent dye;
human metabolite;
plant metabolite
pyridine
azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.		2.1310azaarene;
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
pyridines		environmental contaminant;
NMR chemical shift reference compound
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		2.1510alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
thiazoles
[no description available]		2.25101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
1,2,4-triazole
1,2,4-triazole: RN given refers to 1H-1,2,4-triazole		7.11101,2,4-triazole
hydrazine
diamine : Any polyamine that contains two amino groups.		2.110azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		7.52201,2,3-triazole
1,3,4-oxadiazole
1,3,4-oxadiazole: structure in first source		7.1110
1,3,4-thiadiazole
1,3,4-thiadiazole: structure given in first source		7.1110thiadiazole
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		2.1110
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		5.7130benzenes;
hydroxycoumarin;
methyl ketone
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Benign Neoplasms
[description not available]		03.4620
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.4620